Neurocrine Biosciences Inc (NBIX)
Gross profit margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Gross profit | US$ in thousands | 1,310,300 | 952,400 | 635,200 | 524,400 | 561,400 |
| Revenue | US$ in thousands | 2,355,100 | 1,883,200 | 1,411,600 | 1,107,700 | 994,700 |
| Gross profit margin | 55.64% | 50.57% | 45.00% | 47.34% | 56.44% |
December 31, 2024 calculation
Gross profit margin = Gross profit ÷ Revenue
= $1,310,300K ÷ $2,355,100K
= 55.64%
Neurocrine Biosciences Inc has shown a fluctuating trend in its gross profit margin over the past five years. Starting at 56.44% on December 31, 2020, the margin decreased to 47.34% by December 31, 2021. The decline continued as the margin dropped further to 45.00% on December 31, 2022.
However, there was a positive turn in the following years. By December 31, 2023, the gross profit margin improved notably to 50.57%, indicating better efficiency in managing production costs and generating revenue. The trend continued upwards as of December 31, 2024, reaching 55.64%.
Overall, the recent improvement in the gross profit margin suggests that Neurocrine Biosciences Inc has been able to enhance its profitability and operational efficiency after a period of decline. Monitoring this ratio going forward will be crucial to assess the company's ability to maintain or further improve its profitability.
Peer comparison
Dec 31, 2024